Cardiology: antiplatelet ticagrelor may boost CABG survival

The novel reversible antiplatelet agent ticagrelor was associated with lower mortality from coronary artery bypass graft surgery (CABG) compared with standard clopidogrel (Plavix), according to a subanalysis of the pivotal PLATO trial.

Compared with clopidogrel, ticagrelor cut total mortality by a relative 51% (4.7% versus 9.7%, P<0.01) and cardiovascular mortality by 48% (4.1% versus 7.9%, P<0.01), according to Claes Held et al, Sweden. The mortality advantage came with no excess bleeding risk, the researchers reported online in the Journal of the American College of Cardiology.

Read more.

Bookmark and Share

Post a Comment

Enter this security code

Submit Comment for Moderation